Hydroxychloroquine sulfate: Difference between revisions
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
==Category== | ==Category== | ||
Antimalarial | |||
==US Brand Names== | ==US Brand Names== | ||
| Line 22: | Line 23: | ||
'''| [[Hydroxychloroquine sulfate warnings and precautions|Warnings and Precautions]]''' | '''| [[Hydroxychloroquine sulfate warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Hydroxychloroquine sulfate adverse reactions|Adverse Reactions]]''' | '''| [[Hydroxychloroquine sulfate adverse reactions|Adverse Reactions]]''' | ||
'''| [[Hydroxychloroquine sulfate overdosage|Overdosage]]''' | '''| [[Hydroxychloroquine sulfate overdosage|Overdosage]]''' | ||
'''| [[Hydroxychloroquine sulfate clinical studies|Clinical Studies]]''' | '''| [[Hydroxychloroquine sulfate clinical studies|Clinical Studies]]''' | ||
Latest revision as of 00:17, 8 January 2014
| Hydroxychloroquine sulfate |
|---|
| HYDROXYCHLOROQUINE SULFATE® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications And Usage |
| Contraindications |
| Warnings And Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage And Administration |
| How Supplied |
| Labels And Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Hydroxychloroquine is an antimalarial drug, sold under the trade names Plaquenil, Axemal (in India), Dolquine and Quensyl, also used to reduce inflammation in the treatment of rheumatoid arthritis (see disease-modifying antirheumatic drugs) and lupus. Hydroxychloroquine differs from chloroquine by the presence of a hydroxyl group at the end of the side chain: The N-ethyl substituent is beta-hydroxylated. It is available for oral administration as hydroxychloroquine sulfate (plaquenil) of which 200 mg contains 155 mg base in chiral form. Hydroxychloroquine has similar pharmacokinetics to chloroquine, with quick gastrointestinal absorption and is eliminated by the kidney. Cytochrome P450 enzymes (CYP 2D6, 2C8, 3A4 and 3A5) N-desethylated Hydroxychloroquine to Ndesethylhydroxychloroquine.
Category
Antimalarial
US Brand Names
Hydroxychloroquine sulfate®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Antimalarials are lipophilic weak bases and easily go through plasma membranes. The free base form accumulates in lysosomes (acidic cytoplasmic vesicles) and is then protonated, resulting in concentrations within lysosomes up to 1000 times higher than in culture media. This increases the pH of the lysosome from 4 to 6. Alteration in pH causes inhibition of lysosomal acidic proteases causing a diminished proteolysis effect. Higher pH within lysosomes causes decreased intracellular processing, glycosylation, and secretion of proteins with many immunologic and nonimmunologic consequences. These effects are believed to be the cause of a decreased immune cell functioning such as chemotaxis, phagocytosis and superoxide production by neutrophils.HCQ is a weak diprotic base that can pass through the lipid cell membrane and preferentially concentrate in acidic cyto-plasmic vesicles. The higher pH of these vesicles in macrophages or other antigen-presenting cells limits the association of autoantigenic (any) peptides with class II MHC molecules in the compartment for peptide loading and/or the subsequent processing and transport of the peptide-MHC complex to the cell membrane.Recently a novel mechanism has been described wherein hydroxychloroquine inhibits stimulation of the toll-like receptor (TLR) 9 family receptors. TLRs are cellular receptors for microbial products that induce inflammatory responses through activation of the innate immune system.
As with other quinoline antimalarial drugs, the mechanism of action of quinine has not been fully resolved. The most accepted model is based on hydrochloroquinine, this model involves the inhibition of hemozoin biocrystallization, which facilitates the aggregation of cytotoxic heme. Free cytotoxic heme accumulates in the parasites, causing their deaths.